Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD
|
|
- Jared Carson
- 7 years ago
- Views:
Transcription
1 Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD Assistant Professor Department of Medicine Division of Hematology and Oncology Medical University of South Carolina
2 Objectives Discuss the molecular basis of the current classification of non-hodgkin lymphomas (NHL). Review the principal types of NHL and their prognosis Review therapeutic principles and current questions in the management of the common types of NHL Discuss key epidemiological, prognostic and therapeutic features of the less common types of NHL
3 2008 WHO classification of NHL B small lymphocytic lymphoma Splenic marginal zone lymphoma Lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type Nodal marginal zone lymphoma Follicular lymphoma Primary cutaneous follicular lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma, NOS (T-cell / histiocyte-rich type; primary CNS type ; primary leg skin type & EBV+ elderly type) Diffuse large B-cell lymphoma with chronic inflammation Primary mediastinal large B-cell lymphoma Intravascular large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Large B-cell lymphoma associated with HHV8+ Castleman disease Primary effusion lymphoma Burkitt lymphoma B cell lymphoma, unclassifiable, Burkitt-like B cell lymphoma, unclassifiable, Hodgkin lymphomalike T Adult T-cell lymphoma/leukemia Extranodal T-cell/NK-cell lymphoma, nasal type Enteropathy-associated T-cell lymphoma Hepato-splenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides Sézary syndrome Primary cutaneous CD30+ T-cell lymphoproliferative disorder Primary cutaneous gamma-delta T-cell lymphoma Peripheral T-cell lymphoma, NOS Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma, ALK+ type Anaplastic large cell lymphoma, ALK- type Infectious mononucleosis like PTLD Polymorphic PTLD Monomorphic PTLD (B & T/NK cell types)
4 Modern Diagnosis and Classification of NHL Morphology Flow-cytometry Metaphase Cytogenetics Immunohistochemistry FISH Lichtman MA et al. Lichtman s Atlas of Hematology
5 Lymphoma incidence in the US B-cell 92.0% CLL/SLL 25.3% Lymphoplasmacytic 3.1% Mantle 2.5% Burkitt 1.6% T-cell 8.0% Follicular 16.0% DLBCL 36.2% B- NOS 7.3% MF/SS 2.6% T/NK 2.2% PTCL-NOS 1.5% Angioimmunoblastic 0.3% Anaplastic 1.3% Most NHL are B-Cell derived DLBCL is the most common Blood 107:265, 2006
6 Ann Arbor staging
7 5 years survival 85.6% 85.6% 71.4% 63.8% 52.6% 47.9% 44.7% Follicular Marginal zone CLL/SLL lymphoplasmacytic Mantle cell DLBCL Burkitt There was recent increase in incidence of NHL Survival in DLBCL remains low
8 Diffuse Large B Cell Lymphoma CD 45 H&E 20x Courtesy of Dr. Carl Buckner Hem Path CD 20
9 PET-CT is desirable at diagnosis and essential at restaging
10 No combination chemotherapy has been proven superior to CHOP (cyclophosphamide, doxorubicin, vincristin and prednisone) N Engl J Med 328:1002, 1993
11 Gene microarray profiling defines subtypes of DLBCL N Engl J Med 346:1937, 2002
12 Blood 103:275, 2004
13
14 Probability Rituximab adds to CHOP and increases the chance of cure in DLBCL CHOP RCHOP N Engl J Med 346:235, 2002 J Clin Oncol 24:3121, 2006 Lancet Oncol 7:379, 2006
15 The Revised International Prognostic Index Blood 109:1857, 2007
16 Autologous HSC is superior to standard chemotherapy in relapsed and refractory DLBCL N Engl J Med 333:154, 1995
17 SALVAGE THERAPY IN THE RITUXIMAB ERA
18 Probability of Survival, % Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, By Disease Status P < Sensitive (N=6,337) Resistant (N=453) Years Slide 37 SUM-WW11_36.ppt
19 Graft-versus lymphoma effect can overcome chemotherapy resistance in DLBCL J Clin Oncol 27:426, 2009
20 Probability of Survival, % Probability of Survival after Allogeneic Transplants for Diffuse Large B-Cell Lymphoma, By Disease Status P < Sensitive (N=383) Resistant (N=124) Years Slide 38 SUM-WW11_37.ppt
21 FOLLICULAR LYMPHOMA Normal reactive lymph node Follicular Lymphoma
22 Follicular Lymphomas Express Bcl-2 t(14;18) Follicular Lymphoma Normal Reactive Follicle Warnke et al
23 Warnke et al Follicular Lymphoma Grading Grade I 0-5 centroblasts/hpf Grade II 6-15 centroblasts/hpf Grade III >15 centroblasts/hpf Centrocytes Mixed Centroblasts Small cleaved follicle cells large blastic follicle cells
24 FLIPI- Follicular Lymphoma International Prognostic Index Score Prognosis % Patients OS (10 yr) 0-1 good moderate poor Solal-Céligny et al.
25
26 Age > 60 LoDLi >6 cm Anemia (<12g/dL) B2microglobulin (> ULN) Bone Marrow involvement FLIPI 2 (A) Progression-free survival (PFS) and (B) overall survival (OS) of the training sample (832 patients) according to the Follicular Lymphoma International Prognostic Index 2 (FLIPI2); (C) PFS and (D) OS of the validation sample (231 patients) Federico M et al. JCO 2009;27:
27 THERAPEUTIC PRINCIPLES Indolent, Incurable (?) Stage I, selected stage II (uncomon) Radiation with curative intent Advanced stage (majority of patients) Watch and wait Immunotherapy (Rituximab) Combined Chemoimmunotherapy R-CHOP R-Bendamustine R-CVP R-FCM Radioimmunotherapy Zevalin Bexxar
28 LymphoCare JCO 27:1202, 2009
29 FL- MAINTENANCE THERAPY
30 RELAPSED DISEASE Immunotherapy (Rituximab) Chemotherapy Chemoimmunotherapy Radioimmunotherapy Autologous stem cell transplantation Allogeneic stem cell transplantation Scarceness of comparative data
31 AUTOLOGOUS TRANSPLANTATION IN FL Median FU 13.5 years JCO 25:2554, 2007
32 Probability of Survival, % Probability of Survival after Autologous Transplants for Follicular Lymphoma, By Disease Status P < Sensitive (N=2,030) Resistant (N=172) Years Slide 35 SUM-WW11_34.ppt
33 Probability of Survival, % 100 Probability of Survival after HLA-identical Sibling Donor Transplants for Follicular Lymphoma, By Disease Status P < Sensitive (N=698) Resistant (N=144) Years Slide 36 SUM-WW11_35.ppt
34 MANTLE CELL LYMPHOMA Recently recognized entity Typically advanced stage Frequent extra-nodal involvement (GI) Male predominance (3:1)
35 MIPI score = age (y) (if ECOG > 1) log10(ldh/uln) log10(wbcs per 10 6 L). MCL PROGNOSIS
36 MCL TREATMENT Watch and wait in selected cases Conventional chemoimmunotherapy inferior R-CHOP R-FCM Intense chemoimmunotherapy HyperCVAD/MTX-AraC R-CHOP->R-DHAP Conventional chemoimmunotherapy + Autologous
37 MCL RELAPSED Bortezomib Lenalidomide mtor inhibitors Bendamustine Autologous transplantation Allogeneic transplantaion
38 Probability of Survival, % Probability of Survival after Transplants for Mantle Cell Lymphoma, By Donor Type P < Autologous (N=2,574) Sibling donor (N=498) Unrelated donor (N=325) Years Slide 39 SUM-WW11_38.ppt
39 CUTANEOUS T CELL LYMPHOMA Variable presentation and clinical course Incurable Initial management with skin directed therapies Systemic therapy for visceral or widespread disease Late participation of Hematologist/Medical Oncologist in care
40 PERIPHERAL T CELL LYMPHOMA Foss F M et al. Blood 2011;117:6756
41 PTCL TREATMENT Combination chemotherapy CHOP Combination chemotherapy + autologous transplantation Danileukin diftitoxin Praletrexate ALK inhibitors Brentuximab-vedotin
42 THE BEST OF THE REST B small lymphocytic lymphoma Splenic marginal zone lymphoma Lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type Nodal marginal zone lymphoma Follicular lymphoma Primary cutaneous follicular lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma, NOS (T-cell / histiocyte-rich type; primary CNS type ; primary leg skin type & EBV+ elderly type) Diffuse large B-cell lymphoma with chronic inflammation Primary mediastinal large B-cell lymphoma Intravascular large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Large B-cell lymphoma associated with HHV8+ Castleman disease Primary effusion lymphoma Burkitt lymphoma B cell lymphoma, unclassifiable, Burkitt-like B cell lymphoma, unclassifiable, Hodgkin lymphomalike T Adult T-cell lymphoma/leukemia Extranodal T-cell/NK-cell lymphoma, nasal type Enteropathy-associated T-cell lymphoma Hepato-splenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides Sézary syndrome Primary cutaneous CD30+ T-cell lymphoproliferative disorder Primary cutaneous gamma-delta T-cell lymphoma Peripheral T-cell lymphoma, NOS Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma, ALK+ type Anaplastic large cell lymphoma, ALK- type Infectious mononucleosis like PTLD Polymorphic PTLD Monomorphic PTLD (B & T/NK cell types)
Non-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationAudience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationAudience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationHodgkin and Non-Hodgkin Lymphoma Pre-HCT Data
(Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationNon-Hodgkin Lymphoma in Queensland An Overview 2012
Non-Hodgkin Lymphoma in Queensland An Overview 2012 Acknowledgements The authors acknowledge and appreciate the work of Queensland Health staff that contribute to and participate in the maintenance of
More informationNon-Hodgkin s lymphoma
Non-Hodgkin s lymphoma Univ. Prof. Dr. Werner Linkesch Leiter der Klinischen Abteilung für Hämatologie LKH-Univ. Klinikum Graz Univ. Klinik für Innere Medizin NON-HODGKIN S LYMPHOMA (NHL) Approximately
More informationFollicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center
Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second
More informationNon-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationMedical Policy Manual. Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas. Date of Origin: May 2010
Medical Policy Manual Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas Date of Origin: May 2010 Section: Transplant Last Reviewed Date: August 2015 Policy No: 45.23 Effective Date:
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationNon-Hodgkin s lymphoma. Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz
Non-Hodgkin s lymphoma Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz NON-HODGKIN S LYMPHOMA (NHL) Approximately 1.5 million people worldwide are living with non-hodgkin s lymphoma (NHL), and it is
More informationNon Hodgkin Lymphoma:
Non Hodgkin Lymphoma: Non Hodgkin Lymphoma, often referred to as NHL, is a cancer originating in the lymphocytes, a type of blood cell, which are integral to the body s immune system. Non Hodgkin Lymphoma
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationIndolent Lymphomas. American Academy of Insurance Medicine 121 st Annual Meeting. Hilton LaJolla October 2012
Indolent Lymphomas American Academy of Insurance Medicine 121 st Annual Meeting Hilton LaJolla October 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC,
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More informationRituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008
Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationDiffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition
Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Relative Frequency of B-cell NHL Diffuse large B-cell lymphoma 37 % Follicular lymphoma
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationSubclassifying DLBCL. Diffuse Large B-Cell Lymphoma: Variants & Subtypes. Subclassifying DLBCL
Diffuse Large B-Cell Lymphoma: Variants & Subtypes Patrick Treseler, MD, PhD University of California San Francisco Subclassifying DLBCL An Entity in Search of a Meaningful Classification Subclassifying
More informationLocoregional & advanced esophagus or esophagogastric junction cancer
Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription
More information-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities
More informationPerspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationCutaneous Lymphoma FAST FACTS
Cutaneous Lymphoma FAST FACTS What is Cutaneous Lymphoma? Cutaneous lymphomas are types of non-hodgkin s lymphomas (NHL) that originate in the lymphocytes (white blood cells). Unlike most other types of
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationNon-Hodgkin s lymphomas (NHLs) are a
Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationBone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationPeripheral T-Cell Lymphoma Facts
Peripheral T-Cell Lymphoma Facts No. 25 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572 Highlights l
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationFollicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk is a cancer of the lymphatic system, a type of non-hodgkin lymphoma. Even though more than 12,000 people are diagnosed
More informationLymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
More informationB-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2008 WHO Classification of Lymphoid Neoplasms: Small B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone B-cell lymphoma Hairy
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationMany people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
More informationThe Lymphoma Guide Information for Patients and Caregivers
The Lymphoma Guide Information for Patients and Caregivers Ashton, lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The
More informationBecause non-hodgkin's lymphoma is a more frequent and distinct disease I will discuss it in more details in this site study.
Southern New Hampshire Medical Center Site report 2009 Lymphomas. Roger Hakimian, MD Foundation Hematology/Oncology 10 Prospect Street, Suite 202 Introduction Lymphomas are group of heterogeneous malignancy
More informationLymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
More informationLow grade non-hodgkin Lymphoma
Low grade non-hodgkin Lymphoma www.lymphomas.org.uk The knowledge to challenge lymphatic cancers The Lymphoma Association provides: freephone helpline emotional support for those affected by lymphomas
More informationUnderstanding Non-Hodgkin Lymphoma
Understanding Non-Hodgkin Lymphoma A Guide For Patients, Survivors, and Loved Ones Fourth Edition This guide is an educational resource compiled by the Lymphoma Research Foundation (LRF) that provides
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationIndolent Lymphomas. Dr Ram Malladi
Indolent Lymphomas Dr Ram Malladi Follicular lymphoma is commonest indolent lymphoma INDOLENT LYMPHOMA % of all NHL Follicular Lymphoma 22 Small lymphocytic lymphoma 6 Marginal zone lymphoma 6 Lymphoplasmacytic
More informationHematopoietic Stem Cell Transplantation for Non- Hodgkin Lymphomas
Hematopoietic Stem Cell Transplantation for Non- Hodgkin (80120) Medical Benefit Effective Date: 04/01/13 Next Review Date: 05/16 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 05/10, 05/11, 05/12,
More informationEffective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
More informationUpdate on Diagnosis and Treatment of Lymphoma
Update on Diagnosis and Treatment of Lymphoma Wei Ai, M.D., Ph.D. Assistant Clinical Professor of Medicine May 2010 Cancer Incidence New Cancer Cases Lymphoma 63,000 - NHL 53,600 - HL 75,00 Cancer Death
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationSocial inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
More informationbnmqwertyuiopasdfghjklzxcvbn mqwertyuiopasdfghjklzxcvbnm qwertyuiopasdfghjklzxcvbnmq ertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwerty
bnmqwertyuiopasdfghjklzxcvbn mqwertyuiopasdfghjklzxcvbnm qwertyuiopasdfghjklzxcvbnmq wertyuiopasdfghjklzxcvbnmqw ertyuiopasdfghjklzxcvbnmqwer Follicular Lymphoma Overview tyuiopasdfghjklzxcvbnmqwerty Lymphoma
More informationAbout B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
More informationThe role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.
The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma
More informationEast Midlands Cancer Network Guidelines for the Management of Follicular NHL
East Midlands Cancer Network Guidelines for the Management of Follicular NHL Written by: Dr Matthew Lyttelton, Professor Martin Dyer, Dr Andrew Haynes Consultation Group: EMCN Haematology NSSG Summary
More informationImmunohistochemical classification of malignant lymphomas
Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms
More informationIn the last decade, passive immunotherapy
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationCancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationNon-Hodgkin Lymphoma. Rick, non-hodgkin lymphoma survivor
Non-Hodgkin Lymphoma Rick, non-hodgkin lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society
More informationTreatment and Care of Cancer Patients: Colorectal Cancer, Pancreatic Cancer, Lymphoma, and Bone Metastasis
Treatment and Care of Cancer Patients: Colorectal Cancer, Pancreatic Cancer, Lymphoma, and Bone Metastasis Satellite Conference and Live Webcast Friday, May 10, 2013 8:30 10:30 a.m. Central Time Produced
More informationNon-Hodgkin Lymphoma
Non-Hodgkin Lymphoma What is non-hodgkin lymphoma? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationAPhA Special Report. Non-Hodgkin s Lymphomas: Clinical Features and Treatment Updates. Introduction. A Continuing Pharmacy Education Activity May 2010
APhA Special Report Supplement to Pharmacy Today A Continuing Pharmacy Education Activity May 2010 Non-Hodgkin s Lymphomas: Clinical Features and Treatment Updates Introduction Lymphoma is a hematologic
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationMature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination
More informationState-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr INTRODUCTION
State-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views
More informationLymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH
Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:
More informationJ Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationRéda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France. Oran, May, 8th, 2010
FIRST LINE TREATMENT IN FOLLICULAR LYMPHOMA Current Status Réda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France Oran, May, 8th, 2010 FL is a complex disease One disease, but many profiles 20%
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationAn estimated 55,000 to 60,000 new cases of non- Non-Hodgkin Lymphoma: Diagnosis and Treatment STEPHEN M. ANSELL, MD, PHD, AND JAMES ARMITAGE, MD
SYMPOSIUM ON ONCOLOGY PRACTICE: HEMATOLOGICAL NON-HODGKIN LYMPHOMA: DIAGNOSIS MALIGNANCIES AND TREATMENT Non-Hodgkin Lymphoma: Diagnosis and Treatment STEPHEN M. ANSELL, MD, PHD, AND JAMES ARMITAGE, MD
More informationWhat to know about the B-cell neoplasms Steven H. Swerdlow, M.D.
What to know about the B-cell neoplasms Steven H. Swerdlow, M.D. Bullet points and key words The 2008 Revised WHO monograph on Tumours of the haematopoietic and lymphoid tissues includes many changes among
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationNon-Hodgkin s Lymphoma
LYMPHOMA Non-Hodgkin s Lymphoma About 71,380 people living in the United States will be diagnosed with lymphoma in 2007. This figure includes approximately 8,190 new cases of Hodgkin lymphoma (4,470 males
More informationGuideline for the Management of Non Hodgkin s Lymphomas (NHL) in Adults
Guideline for the Management of Non Hodgkin s Lymphomas (NHL) in Adults Version History Version Date Brief Summary of Change Issued 1.0 11.05.06 Discussed at Governance Committee and approved as a chairman
More informationThe role of PET-CT in Follicular Lymphoma Prognostic and Predictive
The role of PET-CT in Follicular Lymphoma Prognostic and Predictive Judith Trotman University Sydney Massimo Federico University Modena Menton 2012 How we used to look at FL 1. Indolent B-cell lymphoma
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More information